Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, touched on AI's growing role in clinical ...

Closed, agency-only AI platforms that cannot integrate into enterprise ecosystems face vendor-lock risk and likely attrition as clients standardize on hyperscaler-aligned architectures. CMOs should ...

Jiang Li, CEO of Vivalink, continues his conversation with Pharmaceutical Executive, this time discussing the impact of continuous monitoring on patient adherence. Clinical trials continue to ...

PE: Can broad LLMs and smaller, focused LLMs coexist? Rusher: I think they’ll coalesce. It’s already happening where there’s very specific versions of certain LLMs for pharmaceutical research. They ...

A growing cohort without protective immunity, combined with measles’ high basic transmissibility, enables rapid propagation even from small pockets of under-vaccination. Loss of elimination status ...

How are the Rare Disease Evidence Principles (RDEP) reshaping evidentiary expectations? Laksheeta Johari: This is a very exciting time in the rare diseas ...

CEO of Vivalink, continues his conversation with Pharmaceutical Executive, this time discussing the impact of continuous monitoring on patient adherence.

However, in the glass box approach, the raw and timestamped data (such as physiological signals like ECG, temperature, or ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

War in the Middle East disrupts pharmaceutical supply chains in the Gulf region, forcing drugmakers to reroute shipments of ...

Sentynl, a subsidiary of Zydus Lifesciences, entered into a licensing agreement with PRG S&T for Progerinin (SLC-D011), an ...

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, discusses FDA's shift to a single pivotal trial standard, in an effort to streamline drug development without lowering ...